Funding

AMSilk Secures €52M To Scale Production Of Silk-Based Biomaterials

Sep 13, 2025 | By Kailee Rainse

Bavaria-based AMSilk, a specialist in advanced biomaterials made from silk proteins, has raised €52M in a funding round, comprising €30M in equity and €22M in convertible bonds. The round was led by existing investor ATHOS (AT Newtec).

SUMMARY

  • Bavaria-based AMSilk, a specialist in advanced biomaterials made from silk proteins, has raised €52M in a funding round, comprising €30M in equity and €22M in convertible bonds. The round was led by existing investor ATHOS (AT Newtec).

The funds will help AMSilk expand commercial traction and scale up industrial production to meet rising global demand for its silk-based protein materials.

The company has secured multi-year production agreements and set up dedicated facilities with key partners, ensuring large-scale, reliable, and consistent manufacturing across its portfolio.

Read Also - Alchemab Therapeutics Raises Series A Financing Extension

Dr Wolfgang Colberg, Chairman of AMSilk’s Advisory Board stated: “At AMSilk, we are very excited about the enthusiasm of our customers for our products and the high demand we are seeing. With the committed funding from our investors, we can now work with our partners to massively scale-up production. This is a significant step towards establishing a completely new industry in Europe and around the world for high-performance biotech materials that can be used in countless applications.”

Founded in 2008, AMSilk is pioneering Biogenius Materials made from silk proteins, setting new benchmarks in material innovation. Using advanced technologies such as DNA editing, protein engineering and precision fermentation, the company transforms nature-inspired biogenic materials into fibers, yarns, hydrogels, and silk powder.

These high-performance materials deliver breakthrough benefits across textile, homecare, biomedical, and automotive industries, offering sustainable, next-generation solutions for products and customers.

Dr Wolfgang Colberg, Chairman of AMSilk’s Advisory Board stated: “At AMSilk, we are very excited about the enthusiasm of our customers for our products and the high demand we are seeing. With the committed funding from our investors, we can now work with our partners to massively scale-up production. This is a significant step towards establishing a completely new industry in Europe and around the world for high-performance biotech materials that can be used in countless applications.”

About AMSilk

AMSilk develops Biogenius Materials from silk proteins, combining DNA editing, protein engineering, and precision fermentation to create sustainable, high-performance fibers, yarns, hydrogels and silk powder.

Recommended Stories for You